A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Disease/Condition: Follicular Lymphoma
Principal Investigator: Dennis L. Cooper |
A Phase 2 Biomarker Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Disease/Condition: Smoldering Myeloma
Principal Investigator: Madhav V. Dhodapkar |
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma (CA204006)
Disease/Condition: Multiple Myeloma
Principal Investigator: Dhodapkar, Madhav |
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Disease/Condition: Advanced Stage Diffuse Large B-Cell Lymphoma
Principal Investigator: Daniel O. Persky |
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Disease/Condition: Hodgkin Lymphoma
Principal Investigator: Stuart Evan Seropian |
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-cell Lymphoma Patients
Disease/Condition: Anaplastic Large Cell Lymphoma (ALCL) | Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral | other transformed T-cell lymphomas
Principal Investigator: Francine M Foss |
An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thromboythemia Myelofibrosis and Post Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50x109 /L to 100 x 109/L
Disease/Condition: Post Essential Thromboythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis | Primary Myelofibrosis
Principal Investigator: Nikolai Alexandrovich Podoltsev |
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Disease/Condition: Multiple Myeloma
Principal Investigator: Madhav Dhodapkar, M.D. |
Imaging the Effects of R-CHOP and other Anthracycline containing Chemotherapy on Cognitive Function in Patients with high-grade lymphoma
Disease/Condition: Lymphoma
Principal Investigator: Herta H Chao |
Immune Function in T-Cell Lymphoma
Disease/Condition: Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral
Principal Investigator: Francine M Foss |
Maintenance Therapy with Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Disease/Condition: Chronic Lymphocytic Leukemia
Principal Investigator: Terri Lynn Parker |
Ofatumumab vs. Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL (ORCHARDD Trial/ Phase III)
Disease/Condition: Diffuse Large B Cell Lymphoma
Principal Investigator: Stuart Evan Seropian |
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Disease/Condition: Limited-stage Diffuse Large B-Cell Lymphoma
Principal Investigator: Daniel O. Persky |
Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered in a 72-Hour Continuous IV Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine.
Disease/Condition: Myelodysplastic Syndromes
Principal Investigator: Nikolai Alexandrovich Podoltsev |
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Disease/Condition: Graft Versus Host Disease | Leukemia | Myelodysplastic Syndromes
Principal Investigator: Warren Shlomchik, MD |
